Do analysts prefer MDRX or SDGR?

Schrodinger has a consensus target price of $20.50, indicating a potential upside of 7.78%. Given Schrodinger's stronger consensus rating and higher possible upside, analysts clearly believe Schrodinger is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Schrodinger 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29

Which has higher earnings and valuation, MDRX or SDGR?

Veradigm has higher revenue and earnings than Schrodinger. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradigm $1.53B 0.37 N/A N/A N/A Schrodinger $255.87M 5.49 -$103.26M -$0.74 N/A

Does the media favor MDRX or SDGR?

In the previous week, Schrodinger had 4 more articles in the media than Veradigm. MarketBeat recorded 6 mentions for Schrodinger and 2 mentions for Veradigm. Schrodinger's average media sentiment score of 1.17 beat Veradigm's score of -0.23 indicating that Schrodinger is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradigm 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Schrodinger 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CERT or MDRX?

Certara presently has a consensus target price of $8.28, suggesting a potential upside of 9.71%. Given Certara's stronger consensus rating and higher probable upside, research analysts clearly believe Certara is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Certara 1 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.45 Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, CERT or MDRX?

Veradigm has higher revenue and earnings than Certara. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Certara $418.84M 2.75 -$1.60M -$0.45 N/A Veradigm $1.53B 0.37 N/A N/A N/A

Is CERT or MDRX more profitable?

Veradigm has a net margin of 0.00% compared to Certara's net margin of -16.75%. Certara's return on equity of 3.86% beat Veradigm's return on equity. Company Net Margins Return on Equity Return on Assets Certara -16.75% 3.86% 2.65% Veradigm N/A N/A N/A

Does the media favor CERT or MDRX?

In the previous week, Certara had 2 more articles in the media than Veradigm. MarketBeat recorded 4 mentions for Certara and 2 mentions for Veradigm. Certara's average media sentiment score of 1.04 beat Veradigm's score of -0.23 indicating that Certara is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Certara 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradigm 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer GDRX or MDRX?

GoodRx presently has a consensus price target of $4.23, suggesting a potential upside of 24.88%. Given GoodRx's stronger consensus rating and higher possible upside, research analysts clearly believe GoodRx is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GoodRx 3 Sell rating(s) 6 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.08 Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, GDRX or MDRX?

GoodRx has higher earnings, but lower revenue than Veradigm. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GoodRx $796.85M 1.46 $30.44M $0.04 84.63 Veradigm $1.53B 0.37 N/A N/A N/A

Is GDRX or MDRX more profitable?

GoodRx has a net margin of 2.07% compared to Veradigm's net margin of 0.00%. GoodRx's return on equity of 7.22% beat Veradigm's return on equity. Company Net Margins Return on Equity Return on Assets GoodRx 2.07% 7.22% 2.53% Veradigm N/A N/A N/A

Does the media favor GDRX or MDRX?

In the previous week, GoodRx had 1 more articles in the media than Veradigm. MarketBeat recorded 3 mentions for GoodRx and 2 mentions for Veradigm. GoodRx's average media sentiment score of 1.02 beat Veradigm's score of -0.23 indicating that GoodRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GoodRx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradigm 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend MDRX or TDOC?

Teladoc Health has a consensus price target of $7.54, indicating a potential upside of 22.37%. Given Teladoc Health's stronger consensus rating and higher possible upside, analysts plainly believe Teladoc Health is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Teladoc Health 1 Sell rating(s) 10 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has better earnings & valuation, MDRX or TDOC?

Veradigm has higher earnings, but lower revenue than Teladoc Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradigm $1.53B 0.37 N/A N/A N/A Teladoc Health $2.53B 0.44 -$200.32M -$0.99 N/A

Does the media refer more to MDRX or TDOC?

In the previous week, Teladoc Health had 2 more articles in the media than Veradigm. MarketBeat recorded 4 mentions for Teladoc Health and 2 mentions for Veradigm. Teladoc Health's average media sentiment score of 1.22 beat Veradigm's score of -0.23 indicating that Teladoc Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradigm 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Teladoc Health 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend HSTM or MDRX?

HealthStream currently has a consensus price target of $27.00, suggesting a potential downside of 7.34%. Given HealthStream's stronger consensus rating and higher possible upside, equities analysts plainly believe HealthStream is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HealthStream 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, HSTM or MDRX?

HealthStream has higher earnings, but lower revenue than Veradigm. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HealthStream $304.06M 2.80 $18.34M $0.72 40.47 Veradigm $1.53B 0.37 N/A N/A N/A

Does the media favor HSTM or MDRX?

In the previous week, HealthStream had 3 more articles in the media than Veradigm. MarketBeat recorded 5 mentions for HealthStream and 2 mentions for Veradigm. HealthStream's average media sentiment score of 1.58 beat Veradigm's score of -0.23 indicating that HealthStream is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HealthStream 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Veradigm 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Veradigm (MDRX) Competitors

$4.60 +0.05 (+1.10%)

As of 02:28 PM Eastern

Compare

MDRX vs. SDGR, CERT, GDRX, TDOC, and HSTM

Should you buy Veradigm stock or one of its competitors? Veradigm's main competitors and comparable companies include Schrodinger (SDGR), Certara (CERT), GoodRx (GDRX), Teladoc Health (TDOC), and HealthStream (HSTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does Veradigm compare to Schrodinger?

Veradigm (NASDAQ:MDRX) and Schrodinger (NASDAQ:SDGR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

79.1% of Schrodinger shares are owned by institutional investors. 2.3% of Veradigm shares are owned by insiders. Comparatively, 10.1% of Schrodinger shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Veradigm has higher revenue and earnings than Schrodinger.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradigm	$1.53B	0.37	N/A	N/A	N/A
Schrodinger	$255.87M	5.49	-$103.26M	-$0.74	N/A

In the previous week, Schrodinger had 4 more articles in the media than Veradigm. MarketBeat recorded 6 mentions for Schrodinger and 2 mentions for Veradigm. Schrodinger's average media sentiment score of 1.17 beat Veradigm's score of -0.23 indicating that Schrodinger is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradigm	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Schrodinger	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Veradigm has a net margin of 0.00% compared to Schrodinger's net margin of -20.98%. Veradigm's return on equity of 0.00% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradigm	N/A	N/A	N/A
Schrodinger	-20.98%	-16.37%	-8.19%

Schrodinger has a consensus target price of $20.50, indicating a potential upside of 7.78%. Given Schrodinger's stronger consensus rating and higher possible upside, analysts clearly believe Schrodinger is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Schrodinger	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Veradigm has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Schrodinger has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market.

Summary

Schrodinger beats Veradigm on 9 of the 14 factors compared between the two stocks.

How does Veradigm compare to Certara?

Certara (NASDAQ:CERT) and Veradigm (NASDAQ:MDRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Certara presently has a consensus target price of $8.28, suggesting a potential upside of 9.71%. Given Certara's stronger consensus rating and higher probable upside, research analysts clearly believe Certara is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Certara	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.45
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Veradigm has a net margin of 0.00% compared to Certara's net margin of -16.75%. Certara's return on equity of 3.86% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Certara	-16.75%	3.86%	2.65%
Veradigm	N/A	N/A	N/A

Veradigm has higher revenue and earnings than Certara.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Certara	$418.84M	2.75	-$1.60M	-$0.45	N/A
Veradigm	$1.53B	0.37	N/A	N/A	N/A

74.0% of Certara shares are owned by institutional investors. 1.1% of Certara shares are owned by insiders. Comparatively, 2.3% of Veradigm shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Certara has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Veradigm has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

In the previous week, Certara had 2 more articles in the media than Veradigm. MarketBeat recorded 4 mentions for Certara and 2 mentions for Veradigm. Certara's average media sentiment score of 1.04 beat Veradigm's score of -0.23 indicating that Certara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Certara	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradigm	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Certara beats Veradigm on 11 of the 15 factors compared between the two stocks.

How does Veradigm compare to GoodRx?

GoodRx (NASDAQ:GDRX) and Veradigm (NASDAQ:MDRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

GoodRx has higher earnings, but lower revenue than Veradigm.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GoodRx	$796.85M	1.46	$30.44M	$0.04	84.63
Veradigm	$1.53B	0.37	N/A	N/A	N/A

GoodRx has a net margin of 2.07% compared to Veradigm's net margin of 0.00%. GoodRx's return on equity of 7.22% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GoodRx	2.07%	7.22%	2.53%
Veradigm	N/A	N/A	N/A

GoodRx presently has a consensus price target of $4.23, suggesting a potential upside of 24.88%. Given GoodRx's stronger consensus rating and higher possible upside, research analysts clearly believe GoodRx is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GoodRx	3 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.08
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

63.8% of GoodRx shares are held by institutional investors. 5.9% of GoodRx shares are held by company insiders. Comparatively, 2.3% of Veradigm shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

GoodRx has a beta of 1.59, indicating that its share price is 59% more volatile than the broader market. Comparatively, Veradigm has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

In the previous week, GoodRx had 1 more articles in the media than Veradigm. MarketBeat recorded 3 mentions for GoodRx and 2 mentions for Veradigm. GoodRx's average media sentiment score of 1.02 beat Veradigm's score of -0.23 indicating that GoodRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GoodRx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradigm	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

GoodRx beats Veradigm on 13 of the 14 factors compared between the two stocks.

How does Veradigm compare to Teladoc Health?

Veradigm (NASDAQ:MDRX) and Teladoc Health (NYSE:TDOC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

76.8% of Teladoc Health shares are held by institutional investors. 2.3% of Veradigm shares are held by company insiders. Comparatively, 0.7% of Teladoc Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Veradigm has a net margin of 0.00% compared to Teladoc Health's net margin of -7.13%. Veradigm's return on equity of 0.00% beat Teladoc Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradigm	N/A	N/A	N/A
Teladoc Health	-7.13%	-12.15%	-5.83%

Veradigm has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, Teladoc Health has a beta of 2.12, meaning that its stock price is 112% more volatile than the broader market.

Teladoc Health has a consensus price target of $7.54, indicating a potential upside of 22.37%. Given Teladoc Health's stronger consensus rating and higher possible upside, analysts plainly believe Teladoc Health is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Teladoc Health	1 Sell rating(s)	10 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.25

Veradigm has higher earnings, but lower revenue than Teladoc Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradigm	$1.53B	0.37	N/A	N/A	N/A
Teladoc Health	$2.53B	0.44	-$200.32M	-$0.99	N/A

In the previous week, Teladoc Health had 2 more articles in the media than Veradigm. MarketBeat recorded 4 mentions for Teladoc Health and 2 mentions for Veradigm. Teladoc Health's average media sentiment score of 1.22 beat Veradigm's score of -0.23 indicating that Teladoc Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradigm	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Teladoc Health	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Teladoc Health beats Veradigm on 9 of the 14 factors compared between the two stocks.

How does Veradigm compare to HealthStream?

HealthStream (NASDAQ:HSTM) and Veradigm (NASDAQ:MDRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

HealthStream has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, Veradigm has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

HealthStream has a net margin of 6.60% compared to Veradigm's net margin of 0.00%. HealthStream's return on equity of 6.81% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HealthStream	6.60%	6.81%	4.64%
Veradigm	N/A	N/A	N/A

HealthStream has higher earnings, but lower revenue than Veradigm.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HealthStream	$304.06M	2.80	$18.34M	$0.72	40.47
Veradigm	$1.53B	0.37	N/A	N/A	N/A

HealthStream currently has a consensus price target of $27.00, suggesting a potential downside of 7.34%. Given HealthStream's stronger consensus rating and higher possible upside, equities analysts plainly believe HealthStream is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HealthStream	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

69.6% of HealthStream shares are held by institutional investors. 20.4% of HealthStream shares are held by insiders. Comparatively, 2.3% of Veradigm shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, HealthStream had 3 more articles in the media than Veradigm. MarketBeat recorded 5 mentions for HealthStream and 2 mentions for Veradigm. HealthStream's average media sentiment score of 1.58 beat Veradigm's score of -0.23 indicating that HealthStream is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HealthStream	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Veradigm	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

HealthStream beats Veradigm on 11 of the 13 factors compared between the two stocks.

Get Veradigm News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDRX vs. The Competition

Export

Metric	Veradigm	Healthcare Technology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$562.58M	$1.70B	$7.13B	$12.84B
Dividend Yield	N/A	4.70%	2.56%	10.56%
P/E Ratio	23.25	20.40	273.00	25.19
Price / Sales	0.37	88.01	621.18	83.66
Price / Cash	N/A	31.51	77.33	51.83
Price / Book	N/A	5.91	10.33	6.20
Net Income	N/A	-$18.66M	$3.49B	$358.38M
7 Day Performance	-4.37%	-1.39%	-3.19%	-2.28%
1 Month Performance	-6.12%	3.12%	0.09%	-2.45%
1 Year Performance	N/A	-15.47%	17.42%	8.16%

Veradigm Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDRX Veradigm	N/A	$4.60 +1.1%	N/A	-1.1%	$562.58M	$1.53B	23.25	8,000	News Coverage High Trading Volume
SDGR Schrodinger	1.5133 of 5 stars	$19.81 -4.3%	$20.50 +3.5%	+3.6%	$1.46B	$255.87M	N/A	790	Positive News
CERT Certara	1.6164 of 5 stars	$7.99 -1.8%	$8.28 +3.7%	-27.6%	$1.22B	$418.84M	N/A	1,576	Positive News
GDRX GoodRx	4.6215 of 5 stars	$3.49 -1.3%	$4.23 +21.3%	-18.7%	$1.19B	$796.85M	87.15	950
TDOC Teladoc Health	2.698 of 5 stars	$6.29 -2.9%	$7.54 +19.9%	-18.7%	$1.14B	$2.53B	N/A	5,600	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDRX) was last updated on 9/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veradigm (MDRX) Competitors

MDRX vs. SDGR, CERT, GDRX, TDOC, and HSTM

How does Veradigm compare to Schrodinger?

Summary

How does Veradigm compare to Certara?

Summary

How does Veradigm compare to GoodRx?

Summary

How does Veradigm compare to Teladoc Health?

Summary

How does Veradigm compare to HealthStream?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDRX vs. The Competition

Veradigm Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veradigm (MDRX) Competitors

MDRX vs. SDGR, CERT, GDRX, TDOC, and HSTM

How does Veradigm compare to Schrodinger?

Do institutionals & insiders have more ownership in MDRX or SDGR?

Which has higher earnings and valuation, MDRX or SDGR?

Does the media favor MDRX or SDGR?

Is MDRX or SDGR more profitable?

Do analysts prefer MDRX or SDGR?

Which has more volatility and risk, MDRX or SDGR?

Summary

How does Veradigm compare to Certara?

Do analysts recommend CERT or MDRX?

Is CERT or MDRX more profitable?

Which has higher valuation and earnings, CERT or MDRX?

Do institutionals and insiders hold more shares of CERT or MDRX?

Which has more risk & volatility, CERT or MDRX?

Does the media favor CERT or MDRX?

Summary

How does Veradigm compare to GoodRx?

Which has preferable earnings and valuation, GDRX or MDRX?

Is GDRX or MDRX more profitable?

Do analysts prefer GDRX or MDRX?

Do institutionals & insiders hold more shares of GDRX or MDRX?

Which has more volatility and risk, GDRX or MDRX?

Does the media favor GDRX or MDRX?

Summary

How does Veradigm compare to Teladoc Health?

Do institutionals and insiders have more ownership in MDRX or TDOC?

Is MDRX or TDOC more profitable?

Which has more volatility and risk, MDRX or TDOC?

Do analysts recommend MDRX or TDOC?

Which has better earnings & valuation, MDRX or TDOC?

Does the media refer more to MDRX or TDOC?

Summary

How does Veradigm compare to HealthStream?

Which has more volatility & risk, HSTM or MDRX?

Is HSTM or MDRX more profitable?

Which has better valuation and earnings, HSTM or MDRX?

Do analysts recommend HSTM or MDRX?

Do insiders & institutionals hold more shares of HSTM or MDRX?

Does the media favor HSTM or MDRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDRX vs. The Competition

Veradigm Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools